Back to Search
Start Over
Discovery and preclinical evaluation of KYS202004A, a novel bispecific fusion protein targeting TNF-α and IL-17A, in autoimmune disease models.
- Source :
-
International immunopharmacology [Int Immunopharmacol] 2024 Jul 30; Vol. 136, pp. 112383. Date of Electronic Publication: 2024 Jun 05. - Publication Year :
- 2024
-
Abstract
- The treatment of autoimmune and inflammatory diseases often requires targeting multiple pathogenic pathways. KYS202004A is a novel bispecific fusion protein designed to antagonize TNF-α and IL-17A, pivotal in the pathophysiology of autoimmune and inflammatory diseases. Our initial efforts focused on screening for optimal structure by analyzing expression levels, purity, and binding capabilities. The binding affinity of KYS202004A to TNF-α and IL-17A was evaluated using SPR. In vitro, we assessed the inhibitory capacity of KYS202004A on cytokine-induced CXCL1 expression in HT29 cells. In vivo, its efficacy was tested using a Collagen-Induced Arthritis (CIA) model in transgenic human-IL-17A mice and an imiquimod-induced psoriasis model in cynomolgus monkeys. KYS202004A demonstrated significant inhibition of IL-17A and TNF-α signaling pathways, outperforming the efficacy of monotherapeutic agents ixekizumab and etanercept in reducing CXCL1 expression in vitro and ameliorating disease markers in vivo. In the CIA model, KYS202004A significantly reduced clinical symptoms, joint destruction, and serum IL-6 concentrations. The psoriasis model revealed that KYS202004A, particularly at a 2  mg/kg dose, was as effective as the combination of ixekizumab and etanercept. This discovery represents a significant advancement in treating autoimmune and inflammatory diseases, offering a dual-targeted therapeutic approach with enhanced efficacy over current monotherapies.<br /> (Copyright © 2024. Published by Elsevier B.V.)
- Subjects :
- Animals
Humans
Mice
Chemokine CXCL1 metabolism
Chemokine CXCL1 genetics
HT29 Cells
Autoimmune Diseases drug therapy
Autoimmune Diseases immunology
Mice, Transgenic
Disease Models, Animal
Antibodies, Bispecific therapeutic use
Antibodies, Bispecific pharmacology
Male
Drug Evaluation, Preclinical
Imiquimod
Anti-Inflammatory Agents therapeutic use
Anti-Inflammatory Agents pharmacology
Mice, Inbred DBA
Interleukin-17 metabolism
Tumor Necrosis Factor-alpha metabolism
Psoriasis drug therapy
Psoriasis immunology
Psoriasis chemically induced
Recombinant Fusion Proteins therapeutic use
Recombinant Fusion Proteins pharmacology
Arthritis, Experimental drug therapy
Arthritis, Experimental immunology
Macaca fascicularis
Subjects
Details
- Language :
- English
- ISSN :
- 1878-1705
- Volume :
- 136
- Database :
- MEDLINE
- Journal :
- International immunopharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 38843642
- Full Text :
- https://doi.org/10.1016/j.intimp.2024.112383